65 related articles for article (PubMed ID: 37365207)
1. Comparison of allo-SCT, auto-SCT and chemotherapy for the treatment of patients with low- or intermediate-risk acute myeloid leukemia: a network meta-analysis.
Ye W; Wu X; Zhao R; Jin X; Li H; Qu Y; Ji J; Liu Z
Stem Cell Res Ther; 2024 May; 15(1):153. PubMed ID: 38816870
[TBL] [Abstract][Full Text] [Related]
2. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.
Moustafa MA; Ramdial JL; Tsalatsanis A; Khimani F; Dholaria B; Bojanini L; Brooks T; Zain J; Bennani NN; Braunstein Z; Brammer JE; Beitinjaneh A; Jagadeesh D; Weng WK; Kumar A; Kharfan-Dabaja MA; Ahmed S; Murthy HS
Transplant Cell Ther; 2024 May; 30(5):516.e1-516.e10. PubMed ID: 38431075
[TBL] [Abstract][Full Text] [Related]
3. Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation.
Richter S; Böttcher M; Stoll A; Zeremski V; Völkl S; Mackensen A; Ekici AB; Jacobs B; Mougiakakos D
Transplant Cell Ther; 2024 Jun; 30(6):628.e1-628.e9. PubMed ID: 38460727
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma.
Schmidt WM; Perera ND; Buadi FK; Hayman SR; Kumar SK; Dispenzieri A; Dingli D; Cook J; Lacy MQ; Kapoor P; Leung N; Muchtar E; Warsame RM; Kourelis T; Binder M; Gonsalves WI; Hogan WJ; Gertz MA
Blood Cancer J; 2023 Aug; 13(1):126. PubMed ID: 37591876
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.
Reddy N; Savani BN
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1265-72. PubMed ID: 21621630
[TBL] [Abstract][Full Text] [Related]
6. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma.
Zhang Y; Rose A; Khadka S; Cao B; Eatrides J; Saeed H; Shah BD; Chavez J; Bello C; Lazaryan A; Khimani F; Ibarz JP; Liu HD; Locke FL; Jain MD; Zhang L; Kharfan-Dabaja MA; Kim J; Ayala E; Nishihori T; Sokol L
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38740140
[TBL] [Abstract][Full Text] [Related]
7. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.
van Besien K
Curr Opin Oncol; 2011 Nov; 23(6):681-91. PubMed ID: 21946246
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place?
Gahrton G; Iacobelli S; Garderet L; Yakoub-Agha I; Schönland S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32664274
[TBL] [Abstract][Full Text] [Related]
9. The reparative immunologic consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
Guisado D; Talware S; Wang X; Davis A; Fozilov E; Etra A; Colombel JF; Schaniel C; Tastad C; Levine JE; Ferrara JLM; Chuang LS; Sabic K; Singh S; Marcellino BK; Hoffman R; Cho J; Cohen LJ
bioRxiv; 2024 Jun; ():. PubMed ID: 38895305
[TBL] [Abstract][Full Text] [Related]
10. Allo or auto CAR-T cells for refractory BCP-ALL?
Bader P
Blood; 2023 Jul; 142(2):122-124. PubMed ID: 37440268
[No Abstract] [Full Text] [Related]
11. Standardisation is the key to the sustained, rapid and healthy development of stem cell-based therapy.
Zhang J; Suo M; Wang J; Liu X; Huang H; Wang K; Liu X; Sun T; Li Z; Liu J
Clin Transl Med; 2024 Apr; 14(4):e1646. PubMed ID: 38572666
[TBL] [Abstract][Full Text] [Related]
12. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
14. Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Kaddu-Mulindwa D; Gödel P; Kutsch N; Heger JM; Scheid C; Borchmann P; Holtick U; Held G; Thurner L; Bewarder M; Rixecker T; Bittenbring JT
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e498-e506. PubMed ID: 35094950
[TBL] [Abstract][Full Text] [Related]
15. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation.
Baek DW; Moon JH; Lee JH; Kang KW; Lee HS; Eom HS; Lee E; Lee JH; Lee JO; Park SK; Kim SJ; Yoo KH; Yoon SS; Koh Y; Kang HJ; Won JH; Lyu CJ; Hahn SM; Lee JH; Park JS; Jo JC; Mun YC; Yang DH; Song GY; Lim SN; Sohn SK;
Blood Cancer J; 2023 Jun; 13(1):95. PubMed ID: 37365207
[TBL] [Abstract][Full Text] [Related]
16. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
